Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 04457845

Drug Profile

PF 04457845

Alternative Names: PF-04457845; PF-4457845

Latest Information Update: 05 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Linkoping University; Pfizer; SpringWorks Therapeutics; Stockholm Centre for Dependency Disorders
  • Class Benzylidene compounds; Piperidines; Pyridazines; Small molecules
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psychiatric disorders
  • Discontinued Alcoholism; Pain; Post-traumatic stress disorders

Most Recent Events

  • 23 Oct 2018 Stockholm Centre for Dependency Disorders terminates a phase-II clinical trials in Alcoholism and Post traumatic stress disorder in Sweden (PO) (ISRCTN56834832)
  • 24 Jun 2018 Biomarkers information updated
  • 29 Dec 2017 Yale University plans the FAAH-I MULTI phase II trial for Substance-related-disorders in March 2018 , (NCT03386487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top